- Home
- MCY vs RNA Comparison
MCY vs RNA Comparison
Compare MCY & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCY | RNA |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCY | RNA |
|---|---|---|
| Price | $90.76 | $72.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | ★ $100.00 | $69.26 |
| AVG Volume (30 Days) | 201.2K | ★ 1.9M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.93 | N/A |
| Revenue | ★ $5,814,768,000.00 | $20,868,000.00 |
| Revenue This Year | $10.03 | $88.12 |
| Revenue Next Year | $4.40 | $18.11 |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | 5.93 | ★ 106.27 |
| 52 Week Low | $46.81 | $21.51 |
| 52 Week High | $96.50 | $72.70 |
Technical Indicators
Market Signals| Indicator | MCY | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 72.72 |
| Support Level | $88.31 | $72.23 |
| Resistance Level | $91.30 | $72.70 |
| Average True Range (ATR) | 2.05 | 0.17 |
| MACD | -0.32 | -0.14 |
| Stochastic Oscillator | 46.76 | 74.29 |
Price Performance
Historical ComparisonAbout MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.